A condition, known commonly as "black urine disease" or Alkaptonuria is a rare genetic disorder involving protein metabolism, and it has its root in the mutation of the homogentisate 1,2-dioxygenase gene, which in turn causes homogentisic acid accumulation in the body. The appearance of dark urine after exposure to air is due to this kind of accumulation; however, a variety of symptoms can be expected, such as joint stiffness, changes in pigmentation, and other long-term health complications. Although the prevalence has been estimated to be between 1 in 250,000 and 1 in 1 million people in the United States, its effects are indeed high on those affected.

Alkaptonuria is an autosomal recessive disease, meaning that the child must inherit a defective copy of the HGD gene from both parents. If both parents are carriers, their offspring have a 25% chance of inheriting two faulty genes and developing alkaptonuria. The condition is genetic but is often not diagnosed for years because it progresses slowly and its early symptoms appear to be harmless.

Symptoms of Alkaptonuria

The most characteristic and common initial symptom of alkaptonuria is dark urine. The reason for this is due to the fact that excess HGA is excreted in the urine and upon oxidation in the presence of air, it gives the urine a brown or black color. Though it is often considered cosmetic, the long-term accumulation of HGA within the connective tissues produces more complicated health problems.

Progressive joint pain and stiffness: The accumulation of HGA in cartilage leads to early-onset osteoarthritis, making movement increasingly difficult over time.

Skin and eye pigmentation changes: Affected individuals may develop bluish or grayish discoloration of the sclera (white part of the eye) and the skin, particularly in areas exposed to friction.

Cardiovascular and respiratory problems: With age, HGA accumulation can lead to valve calcifications in the heart and stiffening of connective tissues in the respiratory tract, which can cause problems in middle and old age.

Decreased mobility and spinal problems: The spine may become stiff and painful due to chronic cartilage degeneration.

These symptoms usually begin to manifest during adulthood, leading to severe complications in a person's 40s or 50s and significantly affecting the quality of their life.

How is Alkaptonuria Diagnosed?

Because of its rarity, alkaptonuria is often mistaken or overlooked early in life. However, there are several ways to confirm the condition:

Urine Testing: The gold standard in the diagnosis is the testing of urine samples for high levels of homogentisic acid via gas chromatography. In case of oxidation, which changes the color of urine to black, it is indicative of alkaptonuria.

Genetic Testing: Confirmatory genetic testing reveals mutations of the HGD gene to diagnose the condition conclusively.

Blood Tests: High levels of HGA in the blood can be used as further evidence.

Imaging Studies: X-rays and MRIs will expose cartilage and joint damage characteristic of alkaptonuria.

Management of Alkaptonuria: Is There A Cure?

At present, there is no cure for alkaptonuria; however, various treatment approaches can reduce its symptoms and slow the disease's progress:

Nitisinone Therapy: Nitisinone is a drug that inhibits the production of HGA. It has been shown to reduce HGA levels and slow tissue damage. However, it needs to be taken under close medical supervision because of potential side effects.

Low-Protein Diet: Since HGA is a byproduct of protein metabolism, reducing protein intake—especially foods rich in tyrosine and phenylalanine—may help decrease HGA production.

Pain Management: OTC pain relievers and anti-inflammatory medications can be used to relieve joint pain and stiffness.

Physical Therapy: Exercise regularly, as it may improve mobility and strengthen muscles, thus reducing strain on affected joints.

Surgical Interventions: Most people with alkaptonuria develop severe osteoarthritis necessitating joint replacement in their old age. Also, some may require heart valve replacement surgery if cardiovascular complications develop.

Life with Alkaptonuria

Although alkaptonuria is not fatal, it severely affects the quality of life. The progressive deterioration of the joints and associated symptoms can make everyday activities difficult, requiring lifestyle changes and medical interventions. The disease may cause premature aging of the joints, requiring walking aids and mobility assistance earlier than expected.

Ongoing research will continue to work on improving the treatment options by focusing on gene therapy and alternative enzyme replacement therapies. However, because of its rarity, the clinical trials and research remain sparse.

As genetic research advances, more hope for better management and possible curative approaches for alkaptonuria exists. Scientists are searching extensively for enzyme replacement therapies and innovative drugs that can target the root cause of the disorder. Being aware and being diagnosed early helps individuals better their condition and ultimately have better long-term health outcomes.

Alkaptonuria is a striking example of how one gene mutation can have widespread effects on the body. Though still a rare and often misunderstood condition, growing awareness and advances in treatment are paving the way for better care. If you or a loved one suspect symptoms of alkaptonuria, it is essential to seek early diagnosis and medical guidance to manage the disease effectively and preserve quality of life.

Hepatitis remains one of the most misunderstood liver conditions, largely because it isn't a single disease but a group of infections—A, B, C, D, and E—each of which behaves very differently once it enters the body.

The question "can hepatitis be cured?" doesn't have one straightforward answer. The truth lies somewhere between full recovery and lifelong management, depending entirely on which type of hepatitis a person has contracted.

Not All Hepatitis Is the Same

Hepatitis A and E are generally short-lived infections. The liver, in most cases, clears these viruses naturally without any specific antiviral medication. Rest, hydration, a balanced diet, and avoiding alcohol are usually enough to help the body recover fully. Chronic infection is rare with these two types, and when it does occur, particularly with Hepatitis E in people with weakened immunity, it can still be treated successfully.

Hepatitis C tells a much more encouraging story. Thanks to advances in medicine, Direct-Acting Antivirals, or DAAs, now cure more than 95 percent of cases. These are oral tablets taken for roughly eight to twelve weeks, and they carry minimal side effects compared to older treatments. For patients diagnosed early, Hepatitis C is, quite genuinely, curable.

Where Treatment Manages Rather Than Cures

Hepatitis B and D are a different story altogether. When the infection is acute, the body often fights it off on its own without much trouble.

Chronic cases, though, are far tougher to deal with. As of now, no medication can fully remove the Hepatitis B virus from the body once it settles in. What doctors can do is keep it under control, usually through antiviral tablets or interferon injections, so that it doesn't quietly damage the liver over time and lead to cirrhosis or cancer. For many patients, this isn't a short course of treatment. It's something they may need to stay on for years, and in several cases, for the rest of their lives.

Hepatitis D is considered the more severe of the two, and it only shows up in people who already have Hepatitis B; it cannot infect someone on its own. Treatment choices here are still quite limited. A few newer drugs have shown some promise in keeping the disease in check, but nothing yet counts as an actual cure. When the liver damage has progressed too far, a transplant sometimes becomes the only way forward.

Why Early Diagnosis Changes The Outcome

The single most important factor in determining outcomes across all types of hepatitis is timing. Detected early, Hepatitis C can be eliminated. Detected early, Hepatitis B can be controlled well enough that liver damage never progresses. Left unchecked, however, both can silently damage liver tissue for years before symptoms even appear.

Regular liver function tests, hepatitis screening for those at risk, and vaccination—especially for Hepatitis B—remain the strongest tools available for prevention and timely intervention.

The Bottom Line

Hepatitis doesn't follow a single script, and that's something patients often find confusing at first. Some forms clear up completely with the right treatment, others require ongoing management to keep the virus in check, and in many cases, vaccination and timely screening make the real difference in avoiding complications down the line.

Knowing exactly which type of hepatitis one is dealing with is what allows a doctor and patient to set realistic expectations and work out a treatment plan that actually fits the situation.

The rise of GLP-1 medications such as Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound (tirzepatide) has transformed obesity and diabetes treatment.

However, soaring demand and earlier drug shortages also fueled the rapid growth of compounded GLP-1 drugs, which are now under increasing scrutiny from regulators and medical experts.

Over the past few months, the U.S. Food and Drug Administration (FDA) has intensified its crackdown on compounded GLP-1 products, warning that patients could face quality, dosing, and safety concerns if they obtain these medications from unlawful sources.

What Are Compounded GLP-1 Drugs?

A compounded drug is a medication that is custom-made by a licensed compounding pharmacy to meet an individual patient's specific medical needs. For example, removing an allergen, changing the dosage, or preparing a formulation that is not commercially available.

The FDA said, "Compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed."

Also read: People Are Microdosing GLP-1 Weight Loss Drugs; What Do Experts Have To Say About It?

Why Have Compounded GLP-1 Drugs Become Popular?

Demand for GLP-1 medications for weight loss skyrocketed worldwide between 2022 and 2025, leading to shortages of semaglutide and tirzepatide.

During these shortages, compounding pharmacies were legally allowed under specific circumstances to prepare several versions of these medications.

Many patients turned to compounded GLP-1s because they were often affordable, available, and easier to buy online.

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

FDA Is Tightening Scrutiny

FDA's efforts to restrict this practice include widespread compounding of semaglutide, tirzepatide, and liraglutide.

The agency has proposed excluding these drugs from the list of bulk substances used for large-scale compounding because FDA-approved alternatives are now available.

It has also issued warning letters to companies producing compounded GLP-1 products outside permitted circumstances.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

Recent Research Raises New Concerns

A new University of Colorado Anschutz Medical Campus secret shopper study published in July 2026 found that the compounded GLP-1 market remains active even after shortages have been curbed.

Researchers reported that many online pharmacies were still selling compounded semaglutide or tirzepatide, with some products originating from pharmacies lacking compounding licenses.

Potential Risks of Compounded GLP-1 Drugs

Inaccurate Dosing

Small differences in concentration may result in patients receiving too much or too little medication.

Sterility Concerns

Injectable medicines must be manufactured under strict sterile conditions. Improper preparation increases the risk of contamination.

Different Ingredients

Some compounded products have reportedly used semaglutide salts or added vitamins and other substances that are not present in FDA-approved versions. The FDA has previously stated that certain semaglutide salt forms have not been demonstrated to be safe or effective.

Limited Safety Data

Because compounded products are not FDA-approved, they have not undergone the rigorous clinical trials evaluating effectiveness, manufacturing consistency, and long-term safety.

Counterfeit or Unregulated Products

Experts warn that some websites advertise compounded GLP-1 medications that may not come from legitimate pharmacies at all.

As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to help manage metabolic disorders and obesity, a new trend is rapidly gaining traction on social media - GLP-1 microdosing.

Instead of taking the prescribed doses approved for diabetes or obesity, some users are deliberately taking much smaller amounts, claiming they can lose weight, reduce food noise, avoid side effects, save money, or even improve longevity.

However, experts warn that there is currently little scientific evidence that GLP-1 microdosing is safe or even effective.

What Is GLP-1 Microdosing?

Some people reduce their dose by extending the time between injections, counting "clicks" on injection pens instead of using prescribed doses, or taking customized low-dose formulations.

HealthandMe spoke to Dr. Shehla Shaikh, Consultant Endocrinologist, Saifee Hospital, Mumbai, about the trend of GLP-1 microdosing.

Dr. Shaikh says, "The lowest dose that is supported by evidence for semaglutide is 0 25 mg. While, for tirzepatide, it is 2 5 mg Some people are using much smaller amounts for example using nine clicks on a semaglutide pen which gives about 0 06 mg. Now there are no randomized studies or clear guidelines that show if this kind of micro-dosing is safe or works."

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

Medical experts caution that these practices fall outside approved prescribing guidelines and have not been rigorously studied.

The expert says, "One big worry is how accurate the dose is. These injectable pens are made to give set approved amounts; not amounts based on people counting clicks. Even a small mistake in counting can mean taking too little medicine which may not work well or too much, which could cause more problems. Since these instructions are complicated, they need careful handling good eyesight and understanding of the device."

Why Are People Trying It?

Fewer Side Effects

Lower Cost

These medications are expensive in various countries. So, people stretch a single prescription by taking less medication than prescribed.

Weight Maintenance

Rather than pursuing significant weight loss, some users say they simply want to maintain previous results or reduce constant food cravings without taking full doses.

Longevity Claims

Online influencers have begun promoting low-dose GLP-1s as potential "longevity drugs." While GLP-1 medications show promise for heart and metabolic health, experts stress that these benefits have only been demonstrated using clinically tested doses, not microdoses.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

The Risks of Microdosing

Reduced Effectiveness

Taking too little medication may fail to adequately suppress appetite, improve blood sugar levels, or achieve meaningful weight loss.

Dr. Shaikh says, "People often choose microdosing because they want to avoid problems reduce appetite with a smaller dose or make a costly medicine last longer. While smaller amounts might help a bit, current information shows that the best and steadiest results come from following the approved ways to take the medicine. Using doses that are too low might not give the results to people who want to lose weight or manage their metabolic health."

Delayed Medical Treatment Or Risk Of Expiration

Experts also say that people with obesity or diabetes could unknowingly receive suboptimal treatment while believing they are protected. Another problem is how long the medicine lasts after it is opened.

Dr. Shaikh explains, "An opened semaglutide pen should be used within 60 days while an opened tirzepatide pen should be used within 30 days. Because microdosing uses the medicine over a longer time, people might keep using it past the time it is safe which could change how good it is."

Inaccurate Dosing

Also read: Could GLP-1 Weight Loss Drugs Help People Take Fewer Sick Days? New Study Says So

Some users manually estimate doses by counting injection pen clicks. Experts warn these devices are designed to deliver specific calibrated doses, making partial dosing unreliable.

The expert says, "Some people think micro-dosing gives similar benefits with fewer problems or lower costs, but this practice has no scientific support and might have several dangers."